Evidence map›Paper›PMID 38622482›Full record

ArticleMolecular biology reports2024

The evaluation of miR-1181 and miR-4314 as serum microRNA biomarkers for epithelial ovarian cancer diagnosis and prognosis.

Yagmur Minareci, Naziye Ak, Hamdullah Sozen, Ozgur A Tosun, Canan Kucukgergin, Fatih Aydin, İlknur Bingul, M Yavuz Salihoglu, Samet Topuz

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. The Role of microRNA in the Prognosis and Diagnosis of Ovarian Cancer.International journal of molecular sciences · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yagmur MinareciFaculty of Medicine, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Istanbul University, Istanbul, Turkey. dryagmurminareci@gmail.com.ORCID http://orcid.org/0000-0003-1420-9318
Naziye AkDepartment of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey.
Hamdullah SozenFaculty of Medicine, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Istanbul University, Istanbul, Turkey.
Ozgur A TosunDepartment of Gynecology and Obstetrics, Division of Gynecologic Oncology, Goztepe Research and Education Hospital, Istanbul Medeniyet University, Istanbul, Turkey.
Canan KucukgerginFaculty of Medicine, Department of Biochemistry, Istanbul University, Istanbul, Turkey.
Fatih AydinFaculty of Medicine, Department of Biochemistry, Istanbul University, Istanbul, Turkey.
İlknur BingulFaculty of Medicine, Department of Biochemistry, Istanbul University, Istanbul, Turkey.
M Yavuz SalihogluFaculty of Medicine, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Istanbul University, Istanbul, Turkey.
Samet TopuzFaculty of Medicine, Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Istanbul University, Istanbul, Turkey.
Istanbul University · TRIstanbul Medeniyet University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimEpithelial ovarian cancer (EOC) is the most ominous tumor of gynecological cancers due to its poor early detection rate and unfavorable prognosis. To date, there is no reliable screening method for the diagnosis of ovarian cancer at an early stage. MiRNAs are small non-coding RNA molecules, and their main function is to regulate gene expression. The present study compared the serum miR-1181 and miR-4314 levels in patients with EOC and healthy controls to measure the diagnostic and prognostic value as candidate biomarkers. MATERIALS AND

methodsWe collected serum samples from a total of 135 participants (69 patients with EOC and 66 healthy controls). Relative expressions of miR-1181 and miR-4314 were measured by quantitative real-time polymerase chain reaction assay (qPCR).

resultsThe present study revealed that both serum miR-1181 and miR-4314 levels in patients with EOC were significantly increased compared to healthy controls for each marker. In addition, there was a significant relationship between miR-1181 and miR-4314 overexpressions and the stage and prognosis of the disease. Finally, patients with high expression levels of miR-1181 and miR-4314 had significantly shorter survival rates than those with low expression levels.

conclusionThe current study proposed that serum miR-1181 and miR-4314 could discriminate the EOC patients from healthy controls. In addition, both miR-1181 and miR-4314 may be predictive biomarkers for ovarian cancer prognosis. Further studies are needed to confirm the findings of the present study.

Indexed as

MicroRNAsNeoplasms, Glandular and EpithelialOvarian NeoplasmsBiomarkers, TumorCarcinoma, Ovarian EpithelialFemaleGene Expression Regulation, NeoplasticHumansReal-Time Polymerase Chain ReactionBiomarkers, TumorMicroRNAsDiagnosisEpithelial ovarian cancerMicroRNAmiR-1181miR-4314Prognosis

Identifiers

PMID38622482
OpenAlexW4394822203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.